Calcium, Voltage-Gated Channels
Cambridge Bioscience, through our collaboration with ChanTest, offers access to screening services to the following voltage-gated calcium channel targets:
Cav1.2/β2/α2δ1
Gene Name: CACNA1C/CACNB2/CACNA2D1
Validated Assay/Platform: IonWorks Quattro™, Manual Patch Clamp, PatchXpress® & QPatch HT
Description: The human CACNA1C gene encodes the pore-forming subunits of Cav1.2. CACNB2 and CACNA2D1 encode auxiliary subunits that modulate gating and pharmacological properties. Cav1.2 channels expressed in heart, smooth muscle, neurons, and endocrine tissue are therapeutic targets in cardiac arrhythmia and hypertension.
Cav1.3/β2/α2δ1
Gene Name: CACNA1D/CACNB3/CACNA2D1
Validated Assay/Platform: FLIPR® & Manual Patch Clamp
Description: The human CACNA1D gene encodes the pore-forming subunit of the neuroendocrine L-type voltage-gated Ca2+ channel. Co-expression with the β3 and α2δ1 auxiliary subunits recapitulates function in heterologous expression.
Cav2.1/β4/α2δ1
Gene Name: CACNA1A/CACNB4/CACNA2D1
Validated Assay/Platform: PatchXpress®, QPatch HT
Description: The human CACNA1A gene encodes the pore-forming subunit of Cav2.1, the voltage-gated P/Q-type calcium channel. CACNB4 and CACNA2D1 encode auxiliary subunits that modulate gating and pharmacological characteristics. Mutations in CACNA1A are responsible for several inherited neurologic disorders including, familial hemiplegic migraine, episodic ataxia type2, and spinocerebellar ataxia type 6 epilepsy. Cav2.1 channels expressed in neurons are therapeutic targets in pain.
Cav2.2/β3/α2δ1
Gene Name: CACNA1B/CACNB3/CACNA2D1
Validated Assay/Platform: IonWorks Quattro™, Manual Patch Clamp, PatchXpress® & QPatch HT
Description: The human CACNA1B gene encodes the pore-forming subunit of Cav2.2, the voltage-gated N-type calcium channel. CACNB3 and CACNA2D1 encode auxiliary subunits that modulate gating and pharmacological properties. Cav2.2 channels expressed in CNS neurons are therapeutic targets in pain.
Cav3.2
Gene Name: CACNA1H
Validated Assay/Platform: IonWorks Quattro™ & PatchXpress®
Description: The human CACNA1H gene encodes the pore-forming subunit of Cav3.2, a voltage-gated T-type calcium channel. Mutations in CACNA1H have been linked to inherited neurologic diseases including idiopathic generalized and childhood absence epilepsies. Cav3.2 channels expressed in CNS neurons and non-neuronal tissues (sinoatrial node, atrioventricular node, kidney, liver, and vascular endothelium) are therapeutic targets in seizure, hypertension, angina, neuropathic pain, insomnia, and cancer.
Platforms Available
Cambridge Bioscience, through our collaboration with ChanTest, offers access to the widest range of screening platforms, from manual patch clamp up to the most recent innovations in automated electrophysiology, allowing you to select the right balance of speed, throughput and data quality to suit your needs.
To find out more about each of these platforms, please Click Here
Request A No Obligation Quote
To discuss an ion channel screening project, please contact our experienced team by Clicking Here
